Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ketone drink tested for appetite effects in obesity

NCT ID NCT06327464

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a ketone supplement drink can change appetite-related hormones in adults with and without obesity. Twenty-six people took part, each receiving the ketone drink on one visit and a placebo on another. Researchers measured hunger and fullness hormones before and after a meal to see if the supplement made a difference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

26 people

The number who actually took part.

Started

Apr 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 19-45 years * Body mass index (BMI): 18.5 - 40.0 kg/m2 * For females: Premenopausal, with regular menstrual cycle (every 21-38 days, by self-report) OR lack of regular menstrual cycles due to oral contraceptive or intrauterine device (IUD) use * Sedentary or recreationally active, defined as: \<300 minutes per week of voluntary exercise at moderate intensity or greater over the past 12 weeks * Not currently pregnant or lactating, not planning to become pregnant in the next 12 weeks * Ability and willingness to fast for 12 hours before each study day visit * If applicable: * For people who occasionally (i.e., \<1x/day) use cannabis (including cannabidiol-based products): ability and willingness to abstain from cannabis for two days prior to each study day visit, the day of each study visit, and during each ad libitum diet phase. * For people who use cannabis daily: ability and willingness to continue to use the exact same amount of cannabis as they normally use for two days prior to each study day visit, the day of each study visit, and during each ad libitum diet phase. Exclusion Criteria: * Current or previous major comorbidities, by self-report, including: * Cardiovascular diseases * Diabetes (type 1 or type 2) * Cancer * Thyroid diseases * Human immunodeficiency virus or hepatitis B or C * Renal diseases * Hepatic diseases * Polycystic ovary syndrome * Uncontrolled/untreated (self-report): * Hypertension * Dyslipidemia * Uncontrolled Ssleep disorders (e.g., insomnia) * Any other condition that may affect appetite and energy balance * Currently or in the past six months: * Use of regular medication or supplement that may affect appetite, energy balance, or sleep * Regular use of tobacco or nicotine products * Starting any new prescription medication within two weeks of the first study day visit or during the study * Working night shifts or traveling across more than 2 time zones within two weeks of and throughout the study * Food intolerances or allergies that cannot be accommodated * History of surgical procedure for weight loss at any time (e.g., gastroplasty, gastric bypass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve); history of extensive bowel resection for other reasons * Current alcohol or substance abuse (score \>2 on the cut down-annoyed-guilty-eye opener \[CAGE\] questionnaire16) * Current or past history of eating disorders including anorexia nervosa, bulimia, binge eating disorder (self-report or score \>20 on the Eating Attitudes Test - 26 \[EATS-26\] questionnaire17) * Weight loss \>5% in past 12 weeks for any reason

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Appetite are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Appetitive Behavior Ketosis Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of British Columbia - Okanagan

    Kelowna, British Columbia, V1V1V7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.